Since metastasized MCC is a very aggressive tumor with poor prognosis and very limited therapeutic options, the presented observations are opening the avenue for targeting the activated PI3K/AKT pathway as an interesting new option for patients suffering from advanced MCC. The gene discussed is AKT1; the disease is neoplasm.